NCT06608329View on ClinicalTrials.gov

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Healthy Adult Subject
Interventions
DRUG

HDM1002

Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.

Trial Locations (1)

Unknown

Hangzhou First People's Hospital, Hangzhou

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06608329 - A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects | Biotech Hunter | Biotech Hunter